8-K - Stoke Therapeutics, Inc. | StockGist

Current Report Details

Event Type

Financial Results+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1924, as amended (the “Exchange Act”), or otherwise subject to the liab

Financial Results

7.01

Regulation FD. On January 11, 2026, the Company issued the Press Release, a copy of which is furnished hereto as Exhibit 99.1 The information furnished with thi

Regulation Fd

8.01

Other Events. The Press Release provides an update related to the design of the Company’s Phase 3 clinical trial of zorevunersen, including the following: Phase

Other Event

$391.7M

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated January 11, 2026 104 Cover Page Interactive Data File (the c

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1